234 results on '"Kim, K."'
Search Results
2. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
3. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
4. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
5. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
6. 48P Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
7. 283P Comparative analysis of osteoporotic fracture (OF) and pathologic fracture (PF) in patients with metastatic colorectal cancer (mCRC) who received palliative chemotherapy
8. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing
9. 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
10. 55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
11. 31P Prognostic significance of the Hounsfield unit when assessing tumors in patients with breast cancer
12. 19P Usefulness of Hounsfield unit on computed tomography, serum neutrophil to lymphocyte ratio, and their combination as prognostic factor in patients with breast cancer
13. 104P Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)
14. 50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients
15. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma
16. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients
17. 1690P A multicenter randomized phase II open label study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer
18. 1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
19. Outcomes after repeated resection for recurrent pulmonary metastases from colorectal cancer
20. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
21. 1609P A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit
22. LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response
23. 1643P Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
24. 1471P Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
25. 1043P First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
26. 987P Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
27. 23P PMC-309: A highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive
28. 118P Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
29. 103P Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
30. 97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
31. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
32. P-025 Prognostic markers to predict efficacy of 5-FU rechallenge as third line chemotherapy in metastatic colorectal cancer
33. SO-7 First-line liposomal irinotecan (nal-IRI), oxaliplatin and S-1 (NASOX) in unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase I/II study
34. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
35. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes
36. Prognostic factors in FIGO stage IB–IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study
37. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes
38. 423P Gut microbiome predicts a response after preoperative chemoradiation in rectal cancer patients
39. 1635P Clinical and pathologic prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
40. Daily skin care habits and the risk of skin eruptions and symptoms in cancer patients
41. External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
42. A PHASE II TRIAL OF GEMCITABINE IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE IN PREVIOUSLY UNTREATED METASETATIC OR RECURRENT PANCREATIC CANCER
43. CHEMOTHERAPY FOR PULMONARY LARGE CELL NEUROENDOCRINE CARCINOMA: SIMILAR TO THAT FOR SMALL CELL LUNG CANCER OR NON-SMALL CELL LUNG CANCER?
44. Significance of smoking history and FDG uptake for pathological N2 staging in clinical N2-negative non-small-cell lung cancer
45. Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
46. SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma
47. P-349 Clinical significance of lymph node radio to predict prognosis in colon cancer
48. Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
49. Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
50. Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.